SBSonia Bakkour

Sonia Bakkour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sonia Bakkour has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial

    by Tippi C. MacKenzie, Billie R Lianoglou, Juan Gonzalez, Christopher C Dvorak, Sandhya Kharbanda, Akos Herzeg, Emma Canepa, Emily M Kreger, Michela Frascoli, Renan Sper, et al.

    In utero hematopoietic cell transplantation (IUHCT) has the potential to treat patients who have hemoglobinopathies by harnessing the unique period of fetal tolerance to maternal cells, thereby enabling semi-allogeneic transplantation without conditioning or immunosuppression. We conducted a phase 1 clinical trial of IUHCT in fetuses with Alpha Thalassemia Major (ATM), a diagnosis that requires serial in utero transfusions (IUT) for survival. We also analyzed outcomes in fetuses with ATM treated with IUT alone in the same time period. Six fetuses underwent transplantation with maternal CD34+ cells (1.33 x 108 ± 2.67x107 cells/kg +1% T cells) at 23.1 ± 1.1 weeks' gestation. All received serial IUT and were delivered at or near term. Perinatal outcomes were broadly similar to those undergoing IUT alone. Two mothers received prophylactic antibiotics because of late positive cultures of harvested cells (without fetal adverse events). Low-level maternal microchimerism was detected in all recipients; T-cell hyporeactivity to maternal antigens was detected in 2/6 offspring but persisted in only one child. Cord blood from ATM-affected pregnancies demonstrated marked expansion of host hematopoietic stem and progenitor cells compared with healthy controls, suggesting a competitive disadvantage for donor cells in this disease context. Neurodevelopmental assessments were largely reassuring, with high quality of life scores. Overall, this protocol was safe and feasible but demonstrates the limitations of IUHCT for ATM without concurrent bone marrow conditioning. The favorable perinatal and neurologic outcomes in most offspring underscore the benefits of prenatal transfusions and the unmet medical need for developing definitive therapies for ATM. NCT02986698


  • Open Access

    Comparison of manual and automated ultrasensitive assays for residual HIV-1 in plasma from individuals on suppressive antiretroviral therapy

    by Sonia Bakkour Coco, Mars Stone, Xutao Deng, Yunfei Wang, Wes Rountree, Salvatore R. Scianna, Leilani Montalvo, Melanie Dimapasoc, Martin Stengelin, George Sigal, et al.

    Several nucleic acid and antigen assays have been developed to detect HIV in plasma at levels below the detection limit of standard clinical assays; however, comparative assessment of performance of these ultrasensitive assays on identical panels has been limited. Here, we report the relative performance characteristics of three manual (ultracentrifugation concentration and laboratory-developed PCR) and two automated commercial assays for single-copy detection of HIV RNA, as well as two ultrasensitive HIV p24 assays, using blinded panels of plasma samples containing HIV at low concentrations. Independent sample sets were studied in two phases: in the first phase, qualification panels consisted of analytic standards in serial dilution and clinical plasma samples from virologically suppressed people with HIV (PWH). HIV detection in clinical samples was infrequent using the ultrasensitive p24 assays (mean 11%). In contrast, a higher proportion of the same samples were detected using single-copy RNA assays (mean 61%). In the second phase, evaluation panels of clinical plasma samples ( n = 80) from virally suppressed PWH and low-copy analytic standards assessed performance of one automated and two manual single-copy RNA assays with the highest qualification phase detection frequencies. The automated assay performed comparably in three separate laboratories and consistently detected HIV RNA in over half (mean 57%) of samples from virally suppressed PWH, whereas the manual assays detected HIV in ≤40% of the same samples. An automated single-copy assay provides a scalable method for measuring residual HIV viremia that may be broadly useful in pathogenesis and cure-directed studies. IMPORTANCE: Most people with HIV (PWH) on antiretroviral therapy have viral loads below the detection limit of clinical assays, yet virus is often present and detectable at very low levels using ultrasensitive research assays. Clinical trials evaluating curative interventions and interpreting outcomes of analytical treatment interruptions depend on reliable assays to assess and quantify changes in HIV persistence often at very low levels. We conducted a two-stage head-to-head, blinded comparison of multiple ultrasensitive HIV RNA and p24 assays, first using 50 low viral load plasma samples, then further evaluating the top-performing assays on a 144-member blinded panel composed of duplicate contrived and clinical specimens from well-suppressed PWH. Single-copy RNA methods performed better than p24 assays, and a fully automated, 9-replicate commercial RNA assay demonstrated high sensitivity, reproducibility across laboratories, and practical scalability that can be applied to measure the impact of interventions in HIV cure trials.


  • Open Access

    Suppressed HIV antibody responses following exposure to antiretrovirals—evidence from PrEP randomized trials and early antiretroviral treatment initiation studies

    by Vivian I. Avelino-Silva, Mars Stone, Sonia Bakkour, Clara Di Germanio, Michael Schmidt, Ashtyn L. Conway, David Wright, Eduard Grebe, Brian Custer, Steven H. Kleinman, et al.


  • Clinical performance of a new multiplex assay for the detection of HIV‐1, HIV‐2, HCV, HBV, and HEV in blood donations in Catalonia (Spain)

    by Silvia Sauleda, Marta Bes, Maria Piron, Edgar Ong, Sonia Bakkour Coco, Jaume Carrió, Jeffrey M. Linnen

    Background: Commercial multiplex nucleic acid tests (NATs) for HIV‐1/HIV‐2/HCV/HBV are widely used in developed countries to screen blood donations. HEV NAT screening has been implemented in some blood banks but is tested with a different assay.Study Design and Methods: This study describes the clinical sensitivity and specificity of the Procleix® UltrioPlex E (UPxE) assay on the automated Procleix Panther® system for the simultaneous detection of HIV‐1/HIV‐2/HCV/HBV/HEV. To evaluate routine performance, 10,138 donations were tested in parallel with UPxE (in ID‐NAT) and current assays (Procleix Ultrio Elite [UE] assay in ID‐NAT and Procleix HEV assay in pool of 16). To assess clinical sensitivity, archived donations positive for HCV, HIV‐1, HBV, HEV, or occult HBV infection (OBI) were tested (n = 104–186).Results: Five donations were initially reactive (IR) with UPxE; none of them were reactive with current assays. Two of the three samples IR for HIV‐1/HIV‐2/HCV/HBV were confirmed positive for HBV (HBV NAT and/or anti‐HBV core positive) and classified as OBI. The two samples IR for HEV were confirmed positive (Procleix HEV assay in ID‐NAT and in‐house RT‐PCR HEV assay). One sample IR for HIV‐1/HIV‐2/HCV/HBV with UPxE and another with UE were not confirmed. UPxE showed a specificity of 99.99% for HIV‐1/HIV‐2/HCV/HBV and 100% for HEV. Comparable sensitivities were observed for HIV‐1, HCV, HBV, OBI, and HEV samples tested in the UPxE, UE, and Procleix HEV assays.Discussion: UPxE may provide an efficient solution for the simultaneous detection of HIV‐1, HIV‐2, HCV, HBV, and HEV in blood donations in a single test.


  • Plasma transfusion–transmission of Zika virus in mice and macaques

    by Koen K. A. Van Rompay, Lark L. Coffey, JoAnn L. Yee, Anil Singapuri, Jackson Stuart, Marion C. Lanteri, Felicia Santa Maria, Kai Lu, Inderdeep Singh, Sonia Bakkour, et al.

    Background: Zika virus (ZIKV) epidemics with infections in pregnant women are associated with severe neurological disease in newborns. Although an arbovirus, ZIKV is also blood transfusion‐transmitted (TT). Greater knowledge of the efficiency of ZIKV TT would aid decisions on testing and pathogen reduction technologies (PRT).Study Design and Methods: Plasma units from ZIKV RNA‐reactive blood donors were used to study infectivity in vitro, in mice, and in macaques. Furthermore, plasma units were subjected to PRT using amotosalen/ultraviolet light A (A/UVA) before transfusion.Results: In vitro infectivity of ZIKV RNA‐reactive plasma varied between 100 and 1000 international units (IU) of ZIKV RNA. Immunodeficient mice were more sensitive with as low as 32 IU sufficient to infect 50% of mice. 50–5500 IU of RNA led to TT in macaques using dose escalation of three different RNA‐positive, seronegative plasma units. In contrast, RNA‐reactive units collected postseroconversion were not infectious in macaques, even at a dose of 9 million IU RNA. After A/UVA PRT, transfusion of plasma containing up to 18 million IU was no longer infectious in vitro and did not result in ZIKV TT in macaques.Conclusion: Significant risks of ZIKV TT are likely confined to a relatively short viremic window before seroconversion, and that sensitive nucleic acid amplification testing likely identifies the majority of infectious plasma. PRT was demonstrated to be effective at preventing ZIKV TT. Considering that there is no approved ZIKV vaccine, these data are relevant to mitigate the risk of TT during the future ZIKV outbreaks.


  • Open Access

    Blood Center Testing Allows the Detection and Rapid Treatment of Acute and Recent HIV Infection

    by Karin van Den Berg, Marion Vermeulen, Sonia Bakkour, Mars Stone, Genevieve Jacobs, Cynthia Nyoni, Coreen Barker, Christopher McClure, Darryl Creel, Eduard Grebe, et al.

    Blood donations in South Africa are tested for HIV RNA using individual donation NAT (ID-NAT), allowing detection and rapid antiretroviral therapy (ART) of acute HIV infections. We enrolled a cohort of acute and recent HIV-infected blood donation candidates in South Africa in 2015–2018, measured HIV antibody, ID-NAT, and recency of infection <195 days (Sedia LAg) at enrollment and initiated early ART. A small cohort of HIV elite controllers was followed without treatment. HIV reservoir measurements included ultrasensitive plasma RNA, cell-associated HIV RNA, and total DNA. Enrollment of 18 Fiebig I–III and 45 Fiebig IV–VI HIV clade C subjects occurred a median of 18 days after index blood donation. ART was administered successfully and compliance with follow-up visits was excellent. There were only minimal differences in HIV reservoir between ART initiation in Fiebig stages I–III vs. IV–VI, but ART noncompliance increased HIV reservoir. In 11 untreated HIV elite controllers, HIV reservoir levels were similar to or higher than those seen in our early treated cohort. National blood services can identify acute HIV cohorts for subsequent HIV cure research studies. Among HIV clade C-infected donors, HIV reservoir differed little by Fiebig stage at treatment initiation, but was smaller than in chronically treated HIV and those with ART noncompliance.


  • Open Access

    The Impact of Early Antiretroviral Treatment (ART) for HIV on the Sensitivity of the Latest Generation of Blood Screening and Point of Care Assays

    by Marion Vermeulen, Cari van Schalkwyk, Genevieve Jacobs, Karin van Den Berg, Mars Stone, Sonia Bakkour, Brian Custer, Ute Jentsch, Michael P. Busch, Edward Murphy, et al.

    Introduction: Rapid initiation of antiretroviral therapy (ART) in early HIV infection is important to limit seeding of the viral reservoir. A number of studies have shown that if ART is commenced prior to seroconversion, the seroconversion may, or may not, occur. We aimed to assess whether seroreversion or no seroconversion occurs using samples collected during an early treatment study in South Africa. Methods: We tested 10 longitudinal samples collected over three years from 70 blood donors who initiated ART after detection of acute or early HIV infection during donation screening on fourth- and fifth-generation HIV antibody and RNA assays, and three point of care (POC) rapid tests. Donors were allocated to three treatment groups: (1) very early, (2) early, and (3) later. Longitudinal samples were grouped into time bins post-treatment initiation. Results: On all three high-throughput HIV antibody assays, no clear pattern of declining signal intensity was observed over time after ART initiation in any of the treatment initiation groups and 100% detection was obtained. The Abbott Determine POC assay showed 100% detection at all time points with no seroreversion. However, the Abbott ABON HIV1 and OraSure OraQuick POC assays showed lower proportions of detection in all time bins in the very early treated group, ranging from 50.0% (95% CI: 26.8–73.2%) to 83.1% (95% CI: 64.2–93.0%), and moderate detection rates in the early and later-treated groups. Conclusion: While our findings are generally reassuring for HIV detection when high-throughput serological screening assays are used, POC assays may have lower sensitivity for detection of HIV infection after early treatment. Findings are relevant for blood safety and other settings where POC assays are used.


  • Open Access

    Mitigating the risk of transfusion‐transmitted infections with vector‐borne agents solely by means of pathogen reduction

    by Susan L. Stramer, Marion C. Lanteri, Jaye P. Brodsky, Gregory A. Foster, David E. Krysztof, Jamel A. Groves, Rebecca L. Townsend, Edward Notari, Sonia Bakkour, Mars Stone, et al.

    Background: This study evaluated whether pathogen reduction technology (PRT) in plasma and platelets using amotosalen/ultraviolet A light (A/UVA) or in red blood cells using amustaline/glutathione (S‐303/GSH) may be used as the sole mitigation strategy preventing transfusion‐transmitted West Nile (WNV), dengue (DENV), Zika (ZIKV), and chikungunya (CHIKV) viral, and Babesia microti, Trypanosoma cruzi, and Plasmodium parasitic infections.Methods: Antibody (Ab) status and pathogen loads (copies/mL) were obtained for donations from US blood donors testing nucleic acid (NAT)‐positive for WNV, DENV, ZIKV, CHIKV, and B. microti. Infectivity titers derived from pathogen loads were compared to published PRT log10 reduction factors (LRF); LRFs were also reviewed for Plasmodium and T. cruzi. The potential positive impact on donor retention following removal of deferrals from required questioning and testing for WNV, Babesia, Plasmodium, and T. cruzi was estimated for American Red Cross (ARC) donors.Results: A/UVA and S‐303/GSH reduced infectivity to levels in accordance with those recognized by FDA as suitable to replace testing for all agents evaluated. If PRT replaced deferrals resulting from health history questions and/or NAT for WNV, Babesia, Plasmodium, and T. cruzi, 27,758 ARC donors could be retained allowing approximately 50,000 additional donations/year based on 1.79 donations/donor for calendar year 2019 (extrapolated to an estimated 125,000 additional donations nationally).Conclusion: Pathogen loads in donations from US blood donors demonstrated that robust PRT may provide an opportunity to replace deferrals associated with donor questioning and NAT for vector‐borne agents allowing for significant donor retention and likely increased blood availability.


  • The Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan

    by Cassandra D. Josephson, Simone Glynn, Sunitha Mathew, Rebecca Birch, Sonia Bakkour, Lisa Baumann Kreuziger, Michael P. Busch, Kathleen Chapman, Carla Dinardo, Jeanne Hendrickson, et al.

    Background: The Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P) is a new iteration of prior National Heart, Lung, and Blood Institute (NHLBI) REDS programs that focus on improving transfusion recipient outcomes across the lifespan as well as the safety and availability of the blood supply.Study Design and Methods: The US program includes blood centers and hospitals (22 including 6 free‐standing Children's hospitals) in four geographic regions. The Brazilian program has 5 participating hemocenters. A Center for Transfusion Laboratory Studies (CTLS) and a Data Coordinating Center (DCC) support synergistic studies and activities over the 7‐year REDS‐IV‐P program.Results: The US is building a centralized, vein‐to‐vein (V2V) database, linking information collected from blood donors, their donations, the resulting manufactured components, and data extracts from hospital electronic medical records of transfused and non‐transfused patients. Simultaneously, the Brazilian program is building a donor, donation, and component database. The databases will serve as the backbone for retrospective and prospective observational studies in transfusion epidemiology, transfusion recipient outcomes, blood component quality, and emerging blood safety issues. Special focus will be on preterm infants, patients with sickle cell disease, thalassemia or cancer, and the effect of donor biologic variability and component manufacturing on recipient outcomes. A rapid response capability to emerging safety threats has resulted in timely studies related to Severe Acute Respiratory Syndrome Corona Virus‐2 (SARS‐CoV‐2).Conclusions: The REDS‐IV‐P program endeavors to improve donor‐recipient‐linked research with a focus on children and special populations while also maintaining the flexibility to address emerging blood safety issues.


  • Minipool testing for SARS‐CoV‐2 RNA in United States blood donors

    by Sonia Bakkour, Paula Saá, Jamel A. Groves, Leilani Montalvo, Clara Di Germanio, Sonja M. Best, Eduard Grebe, Kristin Livezey, Jeffrey M. Linnen, Donna Strauss, et al.

    Background: SARS‐CoV‐2 RNA prevalence in blood donors from large geographic areas of high community transmission is limited. We tested residual donor plasma minipools (MPs) to determine SARS‐CoV‐2 RNAemia prevalence in six United States areas.Study Design/Methods: Blood donations collected from 7 March 2020 to 25 September 2020 were tested for SARS‐CoV‐2 RNA (vRNA) in MP of 6 or 16 donations using the Grifols Procleix SARS‐CoV‐2 research‐use only (RUO) transcription‐mediated amplification (TMA) assay. Reactive results were confirmed using an alternate target region TMA assay. Reactive MPs were tested by TMA after serial dilution to estimate viral load. Testing for anti‐SARS‐CoV‐2 antibodies and infectivity was performed.Results: A total of 17,995 MPs corresponding to approximately 258,000 donations were tested for vRNA. Three confirmed reactive MP16 were identified. The estimated prevalence of vRNA reactive donations was 1.16/100,000 (95% CI 0.40, 3.42). The vRNA‐reactive samples were non‐reactive for antibody, and the estimated viral loads of the (presumed single) positive donations within each MP ranged from <1000 to <4000 copies/ml. When tested, no infectivity was observed in inoculated permissive cell cultures.Discussion: Blood donation MP‐nucleic acid testing (NAT) indicated that SARS‐CoV‐2 RNAemia is infrequent and, when detected, the vRNA was at low concentrations. Only one RNA‐reactive MP could be tested for infectivity for operational reasons and was not infectious in cell culture. These findings support current recommendations from international and national regulatory agencies to not screen donors by NAT.